Drug ID:Drug5
Drug Name:Inositol
CID:892
DrugBank ID:DB13178
Modality:Small Molecule
Groups:NULL
US Approved:NO
Other Approved:YES
Identifier: NCT01111292
Molecular Formula:C6H12O6
Molecular Weight:180.16 g/mol
Isomeric SMILES:C1(C(C(C(C(C1O)O)O)O)O)O
Synonyms:inositol; myo-inositol; 6917-35-7; Myoinositol; mesoinositol; Inosite; Insitolum; Isoinositol; Inositol, i-; Inositol (VAN)
Phase 0: 2
Phase 1: 3
Phase 2: 14
Phase 3: 6
Phase 4: 8
Description:NULL

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
dt32 892 Inositol 5340 PLG Homo sapiens (human) None
dt33 892 Inositol 4893 NRAS Homo sapiens (human) None
dt34 892 Inositol 351 APP Homo sapiens (human) None
dt35 892 Inositol 7157 TP53 Homo sapiens (human) None
dt36 892 Inositol 4907 NT5E Homo sapiens (human) None
dt37 892 Inositol 886385 pssA Mycobacterium tuberculosis H37Rv Inhibitor
dt38 892 Inositol 351 APP Homo sapiens (human) Inhibitor
dt39 892 Inositol 887 CCKBR Homo sapiens (human) None
dt40 892 Inositol 2629 GBA1 Homo sapiens (human) None

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT01111292 Inositol in Preventing Colorectal Cancer in Patients With Colitis-Associated Dysplasia PHASE1|PHASE2 TERMINATED National Cancer Institute (NCI) Colon Carcinoma|Dysplasia in Crohn Disease|Low Gr… DRUG: Inositol|OTHER: Placebo Details
ChiCTR-OCC-14004591 The effect of inositol hexaphosphate and its hydrolysate on the risk of colorectal cancer and the composition of intestinal microbiota Not Available Not Recruiting Medical College of Qingdao University colorectal cancer Case (colorectal cancer) group:a newly diagnosed … Details
NCT05539625 Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis PHASE2 SUSPENDED University of Edinburgh Ulcerative Colitis DIETARY_SUPPLEMENT: MitoQ|OTHER: Placebo Details
NCT03802214 Ulcerative Colitis - Vedolizumab- With/Without Prior Exposure to Anti-TNF锛圱umor Necrosis Factor锛塗herapy None TERMINATED Stanford University Ulcerative Colitis DRUG: Vedolizumab Details
NCT03907631 Multi-centre Acute Severe Ulcerative Colitis Prospective Cohort Study (Elevate ASUC) None ACTIVE_NOT_RECRUITING Hull University Teaching Hospitals NHS Trust Severe Ulcerative Colitis OTHER: Standard of care Details
NCT01100112 (CB-01-02/06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release Tablets PHASE3 COMPLETED Bausch Health Americas, Inc. Colitis, Ulcerative DRUG: Budesonide Details
NCT01759056 Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis PHASE1 COMPLETED Avaxia Biologics, Incorporated Ulcerative Colitis DRUG: AVX 470|DRUG: Placebo Details
NCT01971970 Biomarkers of Anti-TNF Treatment in Inflammatory Bowel Disease (IBD) None COMPLETED Erasmus Medical Center Inflammatory Bowel Diseases BIOLOGICAL: Infliximab|BIOLOGICAL: Adalimumab Details
NCT00295282 A Dose-Escalation Study of MDX-1100 in Patients With Active Ulcerative Colitis PHASE1 COMPLETED Bristol-Myers Squibb Ulcerative Colitis DRUG: MDX-1100 (anti-CXCL10 human monoclonal anti… Details
NCT03298022 Efficacy&Safety of ALTB-168 in Patients With Moderate to Severe Active,Anti-TNF Alpha and/or Anti-integrin Refractory UC PHASE2 TERMINATED AltruBio Inc. Ulcerative Colitis BIOLOGICAL: ALTB-168 Details
NCT01532648 Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA) PHASE3 COMPLETED Bausch Health Americas, Inc. Ulcerative Colitis DRUG: Budesonide MMX|DRUG: Placebo|DRUG: 5-ASA Details
NCT01882205 Comparison Between Chromoendoscopy and Virtual Chromoendoscopy (NBI, I-scan, FICE) for Detection of Neoplasia in Long Standing Ulcerative Colitis None RECRUITING Universitaire Ziekenhuizen KU Leuven Ulcerative Colitis DEVICE: Virtual chromoendoscopy|PROCEDURE: Chromo… Details
NCT04743518 Impact of Anti-TNF, Vedolizumab and Tofacitinib on Aortic Stiffness, Carotid Intima-media Thickness and Cardiovascular Risk of Patients With Ulcerative Colitis None UNKNOWN Centre Hospitalier Universitaire, Amiens Ulcerative Colitis OTHER: Aortic pulse wave velocity|OTHER: carotid … Details
NCT01417702 Endoscopy for Assessment of Mucosal Healing in IBD None COMPLETED University of Erlangen-Nürnberg Medical School Crohns Disease|Ulcerative Colitis DEVICE: High-definition white light endoscopy and… Details
NCT06663605 Phase 1 Study Evaluating PALI-2108 in Healthy Volunteers and Ulcerative Colitis Patients. PHASE1 RECRUITING Palisade Bio Ulcerative Colitis (UC)|Healthy Volunteer DRUG: PALI-2108|DRUG: PALI-2108 Placebo Details
NCT04939025 Multi-interventional Program to Reduce Chronic Ileoanal Pouch Leaks in UC None NOT_YET_RECRUITING London North West Healthcare NHS Trust Ulcerative Colitis PROCEDURE: Multi-interventional program Details
NCT03679546 EFFICACI : EFFicacy of Intravenous Infliximab Versus Vedolizumab After Failure of subCutaneous Anti-TNF in Patients With UlCerative Colitis PHASE4 ACTIVE_NOT_RECRUITING Rennes University Hospital Ulcerative Colitis DRUG: Infliximab|DRUG: Vedolizumab Injection Details
NCT02227602 Anti-Inflammatory Effects of Mango Polyphenolics in Inflammatory Bowel Disease None COMPLETED Texas A&M University Intestinal Diseases|Ulcerative Colitis|Crohn Dise… DRUG: Mango polyphenolics Details
NCT03011268 Anti-tumor Necrosis Factor in Patients With Ulcerative Colitis in Clinical Remission: to Continue or Not? None ACTIVE_NOT_RECRUITING Helse Møre og Romsdal HF Colitis,Ulcerative OTHER: Discontinuation of anti-TNF treatment|OTHE… Details
NCT01294410 Induction and Maintenance Study of BMS-936557 Patients With Moderate to Severe Ulcerative Colitis PHASE2 COMPLETED Bristol-Myers Squibb Colitis, Ulcerative DRUG: Placebo|DRUG: Placebo|DRUG: Anti-IP-10 Anti… Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
S04 T-cell homing and retention T-cell trafficking vedolizumab; anti-MAdCAM1 antibodies ; etrolizumab Inhibition of the interaction between α4β7 integrins on T c… Details

Inhibition of the phosphatidylinositol-3-kinase pathway abrogates polyinosinic:…

PMID: 20836715
Year: 2010
Relationship Type: Mechanism Score: 6.1

BACKGROUND: Inappropriate responses to normal intestinal bacteria may be involved in the development of Inflammatory Bowel Diseases (IBD, e.g. Crohn…

View Details
Showing 21-21 of 21 articles